Thomas R Spitzer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7843600/publications.pdf

Version: 2024-02-01

120 papers 3,610 citations

279798 23 h-index 58 g-index

121 all docs

121 docs citations

times ranked

121

4458 citing authors

#	Article	IF	CITATIONS
1	HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression. New England Journal of Medicine, 2008, 358, 353-361.	27.0	965
2	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
3	Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2016, 316, 2094.	7.4	301
4	Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 2042-2048.	2.0	219
5	Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Advances, 2018, 2, 745-753.	5.2	167
6	Haematopoietic cell transplantation with and without sorafenib maintenance for patients with <i><scp>FLT</scp>3</i> àse <scp>ITD</scp> acute myeloid leukaemia in first complete remission. British Journal of Haematology, 2016, 175, 496-504.	2.5	162
7	Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial. Journal of Clinical Oncology, 2017, 35, 3714-3721.	1.6	153
8	Long-Term Follow-Up of Recipients of Combined Human Leukocyte Antigen-Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With End-Stage Renal Disease. Transplantation, 2011, 91, 672-676.	1.0	143
9	Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation. 2003. 9. 320-329.	2.0	140
10	Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation. Cancer, 2016, 122, 806-812.	4.1	92
11	Dose-Reduced Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation for Human Immunodeficiency Virus–Associated Lymphoma: AIDS Malignancy Consortium Study 020. Biology of Blood and Marrow Transplantation, 2008, 14, 59-66.	2.0	85
12	Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or NaÃ-ve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201. Journal of Clinical Oncology, 2014, 32, 2365-2372.	1.6	77
13	Haploidentical Stem Cell Transplantation: The Always Present but Overlooked Donor. Hematology American Society of Hematology Education Program, 2005, 2005, 390-395.	2.5	47
14	Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach. Human Immunology, 2018, 79, 258-265.	2.4	40
15	Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation. Transfusion Medicine Reviews, 2019, 33, 43-50.	2.0	39
16	Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. American Journal of Hematology, 1996, 51, 164-165.	4.1	35
17	Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. Blood, 2017, 129, 3256-3261.	1.4	34
18	Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance. Advances in Hematology, 2016, 2016, 1-8.	1.0	33

#	Article	IF	CITATIONS
19	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biology of Blood and Marrow Transplantation, 2016, 22, 910-918.	2.0	32
20	Multimodal psychosocial intervention for family caregivers of patients undergoing hematopoietic stem cell transplantation: A randomized clinical trial. Cancer, 2020, 126, 1758-1765.	4.1	32
21	Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation. Cancer, 2018, 124, 2438-2446.	4.1	28
22	Coping and Modifiable Psychosocial Factors are Associated with Mood and Quality of Life in Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 2234-2242.	2.0	28
23	Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer, 1999, 85, 93-99.	4.1	25
24	Engraftment syndrome after allogeneic hematopoietic cell transplantation in adults. American Journal of Hematology, 2014, 89, 698-705.	4.1	23
25	Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. Oncologist, 2018, 23, 624-630.	3.7	21
26	Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned. Transplantation, 2019, 103, 2366-2372.	1.0	19
27	Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 1583-1588.	2.0	18
28	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. Blood, 2019, 134, 211-215.	1.4	18
29	The expanding frontier of hematopoietic cell transplantation. Cytometry Part B - Clinical Cytometry, 2012, 82B, 271-279.	1.5	17
30	Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 730-734.	2.0	16
31	Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 80-85.	2.0	14
32	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy, 2017, 19, 272-284.	0.7	13
33	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica, 2019, 104, 844-854.	3.5	13
34	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances, 2019, 3, 1441-1449.	5.2	12
35	Hematopoietic Stem-Cell Transplantation in the Resource-Limited Setting: Establishing the First Bone Marrow Transplantation Unit in Bangladesh. Journal of Global Oncology, 2018, 4, 1-10.	0.5	11
36	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biology of Blood and Marrow Transplantation, 2019, 25, 699-711.	2.0	11

#	Article	IF	CITATIONS
37	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. Blood Advances, 2020, 4, 706-716.	5.2	11
38	FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation. Blood, 2011, 118, 653-653.	1.4	11
39	Difficulties in hematopoietic progenitor cell collection from a patient with TEMPI syndrome and severe iatrogenic iron deficiency. Transfusion, 2015, 55, 2142-2148.	1.6	10
40	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen–Matched Grafts. Biology of Blood and Marrow Transplantation, 2017, 23, 126-133.	2.0	10
41	Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clinical Cancer Research, 2018, 24, 4098-4109.	7.0	9
42	Conversion to Full Donor Chimerism without Gvhd Using High-Dose DLI in Minimally Conditioned Miniature Swine Recipients of Haploidentical HCT Blood, 2008, 112, 2336-2336.	1.4	9
43	Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1836-1840.	2.0	8
44	Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. Bone Marrow Transplantation, 2020, 55, 758-762.	2.4	7
45	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. Bone Marrow Transplantation, 2020, 55, 2121-2131.	2.4	7
46	Excellent Disease-Free Survival after Double Cord Blood Transplantation Using a Reduced Intensity Chemotherapy Only Conditioning Regimen in a Diverse Adult Population Blood, 2005, 106, 2048-2048.	1.4	7
47	Allele Matching At HLA-C or DRB1 Is Associated with Improved Survival After Reduced Intensity Double Umbilical Cord Blood Transplantation. Blood, 2012, 120, 2010-2010.	1.4	7
48	Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML. Blood, 2014, 124, 671-671.	1.4	7
49	Miniature Swine as a Clinically Relevant Model of Graft-Versus-Host Disease. Comparative Medicine, 2015, 65, 429-43.	1.0	7
50	Donor Lymphocyte Infusion–Mediated Graft-versus-Host Responses in a Preclinical Swine Model of Haploidentical Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1953-1960.	2.0	5
51	Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 2319-2321.	2.4	5
52	Larger Numbers of Donor Nail`ve CD8+ T-Cells and Plasmacytoid Dendritic Cell Precursors In Allogeneic BM Grafts From Unrelated Donors Are Associated with Improved Survival: Results From BMT CTN 0201. Blood, 2011, 118, 1004-1004.	1.4	5
53	Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies. Blood, 2021, 138, 653-653.	1.4	5
54	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biology of Blood and Marrow Transplantation, 2020, 26, 1210-1217.	2.0	4

#	Article	IF	CITATIONS
55	Declining bone marrow harvest quality over 24 years: a single institution experience. Bone Marrow Transplantation, 2021, 56, 983-985.	2.4	4
56	Prognostic understanding, quality of life (QOL), and mood in patients undergoing hematopoietic stem cell transplantation (HCT) Journal of Clinical Oncology, 2014, 32, 219-219.	1.6	4
57	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplantation, 2020, 55, 804-810.	2.4	3
58	A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. PLoS ONE, 2021, 16, e0252995.	2.5	3
59	Pre-Infusion Characteristics of the Predominant Cord Blood Unit Correlate with Hematopoietic Engraftment in the Setting of Non-Myeloablative Double Cord Blood Transplant (DCBT) Blood, 2005, 106, 3027-3027.	1.4	3
60	Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol. Blood, 2010, 116, 906-906.	1.4	3
61	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. Blood, 2013, 122, 695-695.	1.4	3
62	Prognostic Understanding, Quality of Life, and Mood in Patients Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 1296-1296.	1.4	3
63	Transplantation Tolerance through Hematopoietic Chimerism. New England Journal of Medicine, 2022, 386, 2332-2333.	27.0	3
64	The journey of stem cell transplantation in Bangladesh: a hike to the state of the art with collaboration between DMCH and MGH. Blood Advances, 2017, 1, 62-64.	5.2	2
65	Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients. Oncologist, 2021, 26, e2082-e2085.	3.7	2
66	Influence of First-Line Regimens on the Outcomes of High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma Blood, 2004, 104, 931-931.	1.4	2
67	Parathyroid Hormone May Improve Autologous Stem Cell Mobilization Via the Stem Cell Niche Blood, 2005, 106, 1968-1968.	1.4	2
68	Impaired Immune Reconstitution after Cord Blood Transplantation in Adults Is Associated with Delayed Recovery but Not Functional Impairment of CD8+T Cells Blood, 2007, 110, 1057-1057.	1.4	2
69	High Rate of Second Malignancies after Reduced Intensity Double Cord Blood Transplants in Adults Blood, 2008, 112, 1958-1958.	1.4	2
70	Psychological distress during hospitalization for hematopoietic stem cell transplantation to predict lower quality of life and high post-traumatic stress disorder symptoms at 6 months post-transplant Journal of Clinical Oncology, 2015, 33, 9557-9557.	1.6	2
71	Effect of inpatient palliative care during hematopoietic stem cell transplantation (HCT) hospitalization on psychological distress at six months post-HCT Journal of Clinical Oncology, 2017, 35, 10005-10005.	1.6	2
72	Changing Stripes to Avoid Graft Versus Leukemia. Transplantation, 2012, 93, 674-675.	1.0	1

#	Article	IF	Citations
73	Intersection of Hematopoietic Cell and Solid Organ Transplantation: Lessons Learned and Unanswered Questions. Biology of Blood and Marrow Transplantation, 2015, 21, 2037-2038.	2.0	1
74	Cytokine syndromes associated with hematopoietic cellular therapy. Advances in Cell and Gene Therapy, $2021,4,.$	0.9	1
75	Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells. Blood, 2019, 134, 3275-3275.	1.4	1
76	Dose Adjusted IV Busulfan/Cyclophosphamide (BU/CY) and Autologous (AU) Stem Cell Transplantation (SCT) for Recurrent Lymphoma Blood, 2004, 104, 1884-1884.	1.4	1
77	Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM) Blood, 2005, 106, 3661-3661.	1.4	1
78	Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT) Blood, 2006, 108, 3148-3148.	1.4	1
79	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis Blood, 2007, 110, 2016-2016.	1.4	1
80	Long Term Follow-up of Recipients of Combined HLA-Matched Nonmyeloablative Bone Marrow and Kidney Transplantation for Multiple Myeloma with End-Stage Renal Disease Blood, 2009, 114, 3368-3368.	1.4	1
81	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. Blood, 2015, 126, 2022-2022.	1.4	1
82	Hematopoeitic Stem Cell Transplantation in the Developing World: A Case Study of Dhaka Medical College, Bangladesh. Blood, 2015, 126, 5626-5626.	1.4	1
83	Reduced Intensity Conditioning (RIC) with Double Umbilical Cord Blood Transplantation Has Similar Outcomes Compared to RIC Transplantation From Related or Unrelated Adult Donors. Blood, 2010, 116, 2367-2367.	1.4	1
84	Engraftment Syndrome After Allogeneic Hematopoietic Cell Transplantation: Relationship to Acute Gvhd and Impact on Transplant Outcomes. Blood, 2011, 118, 3013-3013.	1.4	1
85	Quality of life and depression during hospitalization for hematopoietic stem cell transplantation to predict quality of life and post-traumatic stress disorder symptoms at 6 months post-transplant Journal of Clinical Oncology, 2015, 33, 215-215.	1.6	1
86	Psychological distress in patients with moderate to severe chronic graft-versus-host disease (cGVHD) Journal of Clinical Oncology, 2018, 36, e22137-e22137.	1.6	1
87	Effect of inpatient palliative care on supportive care measures in patients undergoing hematopoietic cell transplantation (HCT) Journal of Clinical Oncology, 2019, 37, 70-70.	1.6	1
88	Establishing the First Hematopoietic Stem Cell Transplant Unit in Nepal. Transplantation and Cellular Therapy, 2022, 28, 223-224.	1.2	1
89	Panel Reactive Antibodies in Women with Ovarian Cancer Undergoing High-Dose Chemotherapy with Peripheral Stem Cell Rescue: A Case Control Study. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 501-505.	1.8	0
90	Successful Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma over the Age of 70 Years Blood, 2005, 106, 5290-5290.	1.4	0

#	Article	IF	CITATIONS
91	Minimal HLA Disparity and KIR Ligand Compatibility in Host Versus Graft Direction May Facilitate Donor Engraftment Following In Vivo and Ex Vivo T Cell Depleted (TCD) Nonmyeloablative Haploidentical Stem Cell Transplantation for Hematologic Malignancies Blood, 2005, 106, 3668-3668.	1.4	0
92	In Vivo and Ex Vivo T-Cell Depleted (TCD) NonmyeloablativeHaploidentical Stem Cell Transplantation (NSCT) for Hematologic Malignancy (HM) Blood, 2005, 106, 5431-5431.	1.4	0
93	Development of Late over Early Full Donor Chimerism (FDC) Results in Improved Progression-Free and Overall Survival in Patients with Advanced Malignant Lymphomas Receiving Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Blood, 2005, 106, 3665-3665.	1.4	0
94	Fludarabine Treatment Is Associated with Depletion of Host CD4+CD25high, FOXP3+, CTLA-4+ Cells and Increased Incidences of Full Donor Chimerism and GVHD in Non-Myeloablative Haploidentical Hematopoietic Cell Transplant Recipients Blood, 2005, 106, 2898-2898.	1.4	0
95	Outcomes of 40 Adult Patients after Double Cord Blood Transplantation Using a Reduced Intensity Chemotherapy Conditioning Regimen Blood, 2006, 108, 605-605.	1.4	0
96	KIR Ligand Incompatibility in HLA-Identical Sibling Nonmyeloablative Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Blood, 2006, 108, 5371-5371.	1.4	0
97	Non-Myeloablative T-Cell Depleted (TCD) Haploidentical Hematopoietic Cell Transplantation (HCT) Followed by Donor Leukocyte Infusion(s) for Hematologic Malignancies: The MGH Experience Blood, 2007, 110, 5088-5088.	1.4	0
98	Impact of the Addition of Rituximab to Initial CHOP Chemotherapy Compared with CHOP Alone in Patients with Relapsed Diffuse Large B-Cell Lymphoma Who Underwent Autologous Stem Cell Transplantation Blood, 2007, 110, 5124-5124.	1.4	0
99	Cardiac Transplant Followed by High-Dose Melphalan and Autologous Stem Cell Transplantation (ASCT) for Patients with AL Amyloidosis and Severe Heart Failure Blood, 2007, 110, 732-732.	1.4	0
100	HLA Locus-Specific Outcomes in Double Umbilical Cord Blood Reduced Intensity Transplantation (DCBT) in Adults Blood, 2007, 110, 2032-2032.	1.4	0
101	The Type of Upfront Induction Therapy for Newly Diagnosed Multiple Myeloma Patients Has No Significant Impact on Clinical Outcomes after Autologous Hematopoietic Stem Cell Transplantation Blood, 2007, 110, 5128-5128.	1.4	0
102	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NAII VE CD8+ T Cells. Blood, 2008, 112, 1167-1167.	1.4	0
103	Phase 1 Clinical Study of Adoptive Immunotherapy with Delayed Infusion of Alloanergized Donor T Cells to Improve Immune Reconstution after Haploidentical Stem Cell Transplantation Blood, 2008, 112, 1156-1156.	1.4	0
104	A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation Blood, 2009, 114, 1148-1148.	1.4	0
105	Busulfan Dosing May Affect Survival Following Reduced Intensity Stem Cell Transplantation in Patients with Acute Myelogeneous Leukemia Blood, 2009, 114, 4328-4328.	1.4	O
106	Risk Factors Associated with the Development of Pneumonitis After High-Dose Chemotherapy with Cyclophosphamide, BCNU, and Etoposide (CBV) Followed by Autologous Stem Cell Transplant. Blood, 2010, 116, 903-903.	1.4	0
107	Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes,. Blood, 2011, 118, 4066-4066.	1.4	0
108	Immune Reconstitution After Cord Blood Transplantation in Adults Depends on Activity of Thymic Epithelial Cells and Vascular Endothelial Elements,. Blood, 2011, 118, 4075-4075.	1.4	0

#	Article	IF	CITATIONS
109	Histological Assessment of Cutaneous Acute Graft-Versus-Host Disease in a Preclinical Swine Model of Hematopoietic Cell Transplantation and Vascularized Skin Flap Tolerance. Blood, 2012, 120, 1894-1894.	1.4	0
110	Patients' and family caregivers' (FC) quality of life (QOL) and mood during hospitalization for hematopoietic stem cell transplantation (HCT) Journal of Clinical Oncology, 2014, 32, 160-160.	1.6	0
111	Serum Uric Acid Levels during Allogeneic Hematopoeitic Cell Transplantation and Subsequent Graft Versus Host Disease. Blood, 2014, 124, 2493-2493.	1.4	0
112	Randomized trial of an inpatient palliative care intervention in patients hospitalized for hematopoietic stem cell transplantation (HCT) Journal of Clinical Oncology, 2016, 34, 10004-10004.	1.6	0
113	Hematopoietic Stem Cell Transplantation in the Resource-Limited Setting: Establishing the First Bone Marrow Transplant Unit in Bangladesh and Initial Outcomes. Blood, 2016, 128, 2384-2384.	1.4	0
114	Risk Factors and Impact of Neurological Complications after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5742-5742.	1.4	0
115	A multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HCT) survivors Journal of Clinical Oncology, 2017, 35, 10013-10013.	1.6	0
116	The relationship between coping strategies and quality of life (QOL) in patients with chronic graft-versus-host disease (cGVHD) Journal of Clinical Oncology, 2018, 36, e19016-e19016.	1.6	0
117	Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 4587-4587.	1.4	0
118	The association between physical functioning, symptom burden, and coping strategies with quality of life (QOL) in patients with chronic graft-versus-host disease (cGVHD) Journal of Clinical Oncology, 2018, 36, 178-178.	1.6	0
119	Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. Clinical Hematology International, 2019, 1, 201-204.	1.7	0
120	Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases. Blood, 2019, 134, 1978-1978.	1.4	0